A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition

Acne Vulgaris Clinical Trial

Official title:

Bioequivalence Study for an Isotretinoin Pharmaceutical Preparation - Capsules. Open, Crossover, Randomized, Single Dose, Three Treatments, Three Periods and Six Sequences With Meal (Breakfast) Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02498288
• Other study ID #: 200115
• Status: Completed
• Phase: Phase 1
• First received: May 16, 2013
• Last updated: June 9, 2017
• Start date: May 31, 2013
• Est. completion date: July 15, 2013

Study information

• Verified date: June 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, crossover, randomized, single dose, three treatments, three periods and six sequences, single dosage, balanced study to determine Bioequivalence of Isotretinoin. Bioequivalence will be compared between the reference medication one (T1) vs the test medication (T3): (T1 vs T3); and the reference medication two (T2), vs test medication (T3): (T2 vs T3). Finally, treatments T1 vs T2 will be compared statistically to determine if they are bioequivalent.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: July 15, 2013
• Est. primary completion date: July 15, 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Included in study will be male volunteers.

• Ages between 18 and 45 years old.

• BMI (Body Mass Index) between 20 to 26 kilogram/meter square (kg/m^2).

• Anti-doping tests negative results.

• Negative test results for Ac human immunodeficiency virus (HIV), HBsAg (hepatitis B surface antigen), and rapid plasma regain (RPR; syphilis test).

• Clinical biochemical test values: Hematic Biometry, Urine Analysis, Biochemical Profile: (Glucose, Ureic Nitrogen, Urea, Creatinine, Uric Acid, Cholesterol, Triglycerides, Total Proteins, Albumin, Globulin, Bilirubin (total, indirect and direct), Alkaline Phosphatase (ALP), Lactic Dehydrogenase, Asparate aminotransferase (AST), Alanine aminotransferase (ALT), Calcium, Phosphorus, Sodium, Potassium, Chlorine and Iron), Ac HIV, HBsAg and RPR, must fall within an interval between minimum and maximum values in connection to said tests accepted values.

• Normal Electrocardiogram (ECG) and Chest X-rays.

• Complete the scale 'Columbia Suicide Severity Rating Scale' (C-SSRS), before and after each dosification period.

• Obtain a grade of zero in the C-SSRS.

• Signed the Informed Consent corresponding to the bioequivalence study.

• In exception cases, accepted may be a candidate for which any previously mentioned test is exceeded regarding considered valid maximum and minimum accepted normal values, as long as it involves an isolated value and there are no other manifestations which could allow assuming that a given value is related to a disease or is remnant of another. These cases must be approved by clinical area and declared as "Non-clinically significant".

Exclusion Criteria:

• Electrocardiographic Anomalies; radiological

• Anti-doping tests positive results,

• Positive results regarding RPR; HIV and HBsAg tests.

• Personal or family history of allergy to medication in question.

• Having any kind of allergy, since these persons are in higher risk of suffering from medication allergy.

• Tobacco use.

• Persons undergoing any medical treatment.

• Existence of concurrent or intercurrent disease.

• History psychiatric disorder (eg, Major Depressive Disorder, Generalized Anxiety Disorder, Bipolar Disorder (I or II), or schizophrenia).

• Existence of justified doubt regarding questionnaire answers truthfulness.

• Having participated in bioequivalence or bioavailability studies or having donated blood 2 months before the study.

• Presence of clinically important gastrointestinal diseases or malabsorption history during the last year.

• Presence of a medical condition requiring regular medication (with prescription or over-the- counter medication) with systemic absorption.

• Drugs or alcohol addiction history requiring treatment.

• Refuse to take the scale 'C-SSRS, before and after each dosification period.

• Obtain a grade greater than zero in the C-SSRS.

• Do not sign the Informed Consent corresponding to the bioequivalence study.

• Finally, excluded will be all those volunteers not meeting that established in Mexican Official Standard NOM-177-SSA1-1998.

Related Conditions & MeSH terms

• Acne Vulgaris

Intervention

Drug:
• Isotretinoin: Reference Medication 1
Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
• Isotretinoin: Reference Medication 2
Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
• Isotretinoin: Test Medication
Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.

Locations

Country	Name	City	State
Mexico	GSK Investigational Site	Monterrey	Nuevo León

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration-time curve from zero hours to last quantifiable time (AUC0-t)	Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.	Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period
Primary	Area under the plasma concentration-time curve from zero hours to infinite (AUC0-infinity)	Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.	Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period
Primary	Maximum drug concentration (Cmax)	Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.	Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period
Primary	Time to maximum drug concentration (Tmax)	Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.	Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period

External Links

•   Results for study 200115 can be found on the GSK Clinical Study Register.